Dyne Therapeutics (DYN) Depreciation & Amortization (CF) (2019 - 2026)
Dyne Therapeutics' (DYN) quarterly Depreciation & Amortization (CF) came in at $600000.0 in Q1 2026, up 19.52% year-on-year from $502000.0 in Q1 2025, and up 27.12% on a QoQ basis from $472000.0 in Q4 2025.
Dyne Therapeutics (DYN) Depreciation & Amortization (CF) (2019 - 2026) Analysis & Trends
Dyne Therapeutics (DYN) has 8 years of Depreciation & Amortization (CF) data on file, last reported at $600000.0 in Q1 2026.
- On a quarterly basis, Depreciation & Amortization (CF) rose 19.52% year-over-year to $600000.0 in Q1 2026; TTM through Mar 2026 was $2.1 million, a 16.73% increase from a year earlier, with the FY2025 full-year figure at $2.0 million, up 19.55% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $600000.0, up from $472000.0 in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for DYN reached as high as $600000.0 in Q1 2026 and fell as low as $383000.0 in Q4 2022.
- Historically, Depreciation & Amortization (CF) has averaged $445941.2 across 5 years, with a median of $425000.0 in 2022.
- Across the five-year window, Depreciation & Amortization (CF) soared 150.0% in 2022 and decreased 20.0% in 2023, its largest moves.
- Year by year, Depreciation & Amortization (CF) stood at $383000.0 in 2022, then gained by 11.23% to $426000.0 in 2023, then increased by 11.03% to $473000.0 in 2024, then declined by 0.21% to $472000.0 in 2025, then gained by 27.12% to $600000.0 in 2026.
- Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $600000.0 in Q1 2026, $472000.0 in Q4 2025, and $500000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Dyne Therapeutics | 3.94 Bn | 3.94 Bn | - | 600,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 600,000.00 |
| Mar 31, 2026 | 600,000.00 |
| Dec 31, 2025 | 472,000.00 |
| Dec 31, 2025 | 472,000.00 |
| Sep 30, 2025 | 500,000.00 |
| Sep 30, 2025 | 500,000.00 |
| Jun 30, 2025 | 500,000.00 |
| Jun 30, 2025 | 500,000.00 |
| Mar 31, 2025 | 502,000.00 |
| Mar 31, 2025 | 502,000.00 |
| Dec 31, 2024 | 473,000.00 |
| Dec 31, 2024 | 473,000.00 |
| Sep 30, 2024 | 400,000.00 |
| Sep 30, 2024 | 400,000.00 |
| Jun 30, 2024 | 400,000.00 |
| Jun 30, 2024 | 400,000.00 |
| Mar 31, 2024 | 400,000.00 |
| Mar 31, 2024 | 400,000.00 |
| Dec 31, 2023 | 426,000.00 |
| Dec 31, 2023 | 426,000.00 |